Vol , Issue Date of Publication: January 01, 2004
DOI: https://doi.org/10.20529/IJME.2004.002

Views
, PDF Downloads:

Needed: closer scrutiny of clinical trials

C M Gulhati
Abstract:
How many people know that eight patients in Hyderabad who were administered recombinant streptokinase to test its efficacy and safety have died? According to the Genetic Engineering Approval Committee (GEAC), the trial was being conducted by the drug's manufacturer Shantha Biotechnics without taking clearance. Not surprisingly, the company denies the allegation claiming that it had taken permission from the Drugs Controller General, India (DCGI). In this game of passing the buck, no one is shedding any tears on the lives lost or compensating the families of those whose loved ones have died. Without any independent enquiry, the death of 'trial subjects', as they are impersonally called, has been attributed to 'causes other than the use' of the drug!


Copyright and license
©Indian Journal of Medical Ethics 2016: Open Access and Distributed under the Creative Commons license ( CC BY-NC-ND 4.0),
which permits only non-commercial and non-modified sharing in any medium, provided the original author(s) and source are credited.

Full Text

HTML | PDF
Help IJME keep its content free. You can support us from as little as Rs. 500 Make a Donation